MRM
MEDIROM Healthcare Technologies Inc.
There isn't enough reported data to score MRM yet.
TSLA
Tesla, Inc.
TSLA's fundamentals are mixed, but it looks expensive: trading at 437x earnings, more than twice its usual 175x. Analysts expect earnings growth, though they disagree widely on how much.
MRM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate MRM's fundamentals.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
MRM PE Valuation
MRM has no meaningful PE right now: it lost money over the past year.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
MRM Forward outlook
There aren't enough analyst estimates for MRM to show an outlook.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TSLA, with profitability holding steady. However, they disagree widely on these estimates.
MRM Earnings Per Share
MRM and TSLA do not have enough comparable growth data to identify a winner.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA's earnings per share have fallen from their peak: $0.91 over the past year, against $4.30 in late 2023.
MRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3.8M | -87% |
| Q2 2025 | $20.3M | -6.7% |
| Q4 2024 | $30.2M | +35% |
| Q2 2024 | $21.8M | +7.2% |
| Q4 2023 | $22.5M | -5.8% |
| Q2 2023 | $20.3M | +106% |
| Q4 2022 | $23.9M | +132% |
| Q2 2022 | $9.9M | -26% |
MRM's revenue has held roughly level: $4M last quarter, down 83% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 12% | +14 points |
| Q2 2025 | -28% | -19 points |
| Q4 2024 | 13% | +6.2 points |
| Q2 2024 | -18% | -13 points |
| Q4 2023 | -2.3% | +12 points |
| Q2 2023 | -9.6% | +15 points |
| Q4 2022 | 6.6% | +60 points |
| Q2 2022 | -4.9% | +59 points |
MRM's operating margin was 12% last quarter, up 14 points from the same quarter a year ago.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA has the edge over MRM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA's operating margin was 2.6% last quarter, down 3.2 points from the same quarter a year ago, near the bottom of its range since 2019.
MRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | -$2.3M | +$2.7M |
| Q4 2024 | -$6.8M | -$6.2M |
| Q2 2024 | -$5M | -$865.8K |
| Q4 2023 | -$634.9K | +$2.4M |
| Q2 2023 | -$4.2M | -$3.2M |
| Q4 2022 | -$3M | -$2.2M |
| Q2 2022 | -$1M | +$197.1K |
| Q4 2021 | -$825K | -4728% |
MRM has burned cash in most quarters: −$15M over the past year, against −$9M the year before.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA still generates free cash flow, though less than at its 2025 peak: $3.3B over the past year.
MRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +3K shares |
| 1 year | +45% | +2.5M shares |
| 3 years | +85% | +3.6M shares |
MRM has 8M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has the edge over MRM on shareholder dilution, with a more favorable share count trend.
MRM Net Leverage
MRM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has more cash than debt.
MRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 6.2 | Oversold |
MRM's weekly RSI is 22 (oversold) and its Stochastic is 6 (oversold).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
MRM PE vs Consumer Cyclical Sector
| Metric | MRM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MRM has no meaningful PE right now: it lost money over the past year.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
MRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 35% below |
| 20 week MA | $0.74 | 62% below |
| 50 week MA | $1.15 | 76% below |
| 100 week MA | $1.28 | 78% below |
| 200 week MA | $3.21 | 91% below |
MRM is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA has the edge over MRM on trend strength, trading above more of its moving averages.
MRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14.4 | $6.26 | -57% |
| 2022 | $6.26 | $5.58 | -11% |
| 2023 | $5.58 | $5.72 | +2.5% |
| 2024 | $5.72 | $1.05 | -82% |
| 2025 | $1.05 | $2.21 | +110% |
| 2026 YTD | $2.21 | $0.28 | -87% |
MRM's yearly returns have swung widely, from +110% in 2025 to −82% in 2024. It's down 87% so far in 2026.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA has the edge over MRM on returns for 2026, with the stronger performance.